+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 218 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating two different pacing methods for patients with slow heart rates, called bradycardia. This study compares the common right ventricular pacing approach with a newer physiological pacing method that includes His bundle and left bundle area pacing. The trial aims to better understand how these pacing techniques affect patient outcomes, including mortality and heart failure morbidity, in a large group of 2600 patients. Participants will receive a pacemaker implant and be randomly assigned to either right ventricular pacing or physiological pacing. The physiological pacing may involve His bundle pacing or left bundle pacing, but if these are not successful, biventricular pacing will be used. A subgroup of 500 participants will take part in an optional echocardiographic sub-study to assess heart function changes over a 24-month period. Throughout the study, patients will be assessed at baseline and every six months after randomization, with follow-up lasting up to 78 months. Researchers will monitor outcomes such as mortality, heart failure events, device-related safety issues, patient quality of life, symptoms, and pacemaker-derived data like arrhythmias and activity levels. The echocardiographic sub-study will measure specific heart function changes to understand pacing-induced cardiomyopathy. Participants involvement includes implantation, regular follow-up visits, questionnaires, and optional imaging assessments.

Age: 18Years +All GendersPhase Not Applicable
45 locations
S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
P

Actively Recruiting

Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.

Age: 18Years +FEMALEPhase 3
206 locations
A

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects of different exercise programs on pain and function in adults with chronic low back pain. This randomized controlled trial includes otherwise healthy participants aged 18 to 45 who experience pain or functional limitations due to low back pain lasting more than 3 months. The study aims to understand how various exercise types impact pain levels and physical ability. Participants are randomly assigned to one of three groups a control group that continues their usual exercise routine, a running-based intervention group, or a swimmingcycling-based intervention group. The two intervention groups will follow an 8-week combined exercise program consisting of aerobic training running or swimmingcycling, progressive resistance exercises, and flexibility exercises. The program gradually increases in intensity over the 8 weeks to encourage adherence and reduce injury risk. Throughout the study, participants will be assessed using validated measures of pain and disability at three points before starting baseline, after 8 weeks of exercise, and at 12 months to evaluate long-term effects. Researchers will collect self-reported pain scores and functional questionnaires to analyze changes over time. The total study duration allows for monitoring both immediate and lasting impacts of the exercise interventions on low back pain management.

Age: 18Years - 45YearsAll GendersPhase Not Applicable
1 location
O

Actively Recruiting

Researchers are studying the safety and effectiveness of a drug called tacabrutideg for people with B-cell malignancies, a type of cancer that affects white blood cells. These cancers include various forms such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and others. The study aims to find the best dose of tacabrutideg and evaluate how well it works in shrinking or eliminating these cancers. The study has two parts first, a dose escalation phase where different doses of tacabrutideg are tested to find a recommended dose that is safe and tolerable. Then, an expansion phase enrolls more participants to further assess the safety and effectiveness of the selected dose or doses. Tacabrutideg is given orally. The study includes multiple groups of participants with different types of B-cell malignancies, including some specific cohorts like Japanese participants and those who have not previously received certain kinase inhibitors. Participants will visit clinics regularly over about three years for treatment, health checks, blood tests, tumor imaging, and other assessments. Researchers will monitor side effects, measure cancer response, and collect blood samples to study how the drug behaves in the body. The main outcomes include safety, identifying the best dose, and overall cancer response rates. The study is open label, so both participants and doctors know the treatment given.

Age: 18Years +All GendersPhase 1Phase 2
114 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating how two drugs, phenytoin and itraconazole, affect the way pelabresib moves through the body in healthy adults aged 18 to 55. This Phase 1, open-label study aims to understand the interaction between these medications and to assess the safety and tolerability of pelabresib when taken alone or together with these drugs. The study has two parts, each with two treatment periods. In the first part, participants receive a single oral dose of pelabresib alone, followed by a single dose of pelabresib combined with repeated doses of phenytoin. In the second part, participants receive pelabresib alone, then pelabresib combined with repeated doses of itraconazole. These sequential treatments allow researchers to compare the effects of the drugs on pelabresib. Participants will undergo various assessments including blood sampling to measure pelabresib levels up to 72 hours after dosing, monitoring for side effects for about 30 days after the last dose, and health evaluations such as physical exams, vital signs, ECGs, and laboratory tests. The study focuses on measuring pelabresibs maximum concentration, exposure over time, and clearance from the body to understand its pharmacokinetics with and without the other drugs.

Age: 18Years - 55YearsAll GendersPhase 1
1 location
A

Actively Recruiting

Relapsed neuroblastoma is a common and serious childhood cancer that is difficult to treat, especially in high-risk cases where the disease returns after initial treatment or does not respond to standard therapies. This trial aims to improve survival for children aged 1 year and older with relapsed neuroblastoma by testing new combinations of treatments. It is an international, open-label, randomized phase III study designed to develop and evaluate these new therapies while also studying the biology of the disease using biomarker samples. Participants will be randomly assigned to one of two main treatment groups or enrolled in smaller dose confirmation groups testing new drug combinations. The current main treatments include combinations of dinutuximab beta, irinotecan, temozolomide, and bevacizumab given in 12 cycles every three weeks. Additional experimental groups may receive different combinations of these drugs. The trial includes a translational sub-study collecting tumor, blood, and bone marrow samples to better understand neuroblastoma and improve targeted therapies. During the study, patients will receive their assigned treatments over multiple cycles and be closely monitored for safety, treatment response, and quality of life. Researchers will perform various assessments including imaging scans, laboratory tests, and questionnaires to measure progression-free survival, side effects, and overall clinical benefit. Follow-up will continue up to five years after treatment to assess long-term outcomes and collect further data on patient health and disease progression.

Age: 1Year +All GendersPhase 1Phase 2
23 locations
S

Actively Recruiting

Researchers are evaluating the drug STP938, an inhibitor of the enzyme CTPS1, in adults with relapsed or refractory B-cell and T-cell lymphomas. This study aims to determine the safety, tolerability, best dose, and preliminary effectiveness of STP938 in treating these lymphomas. The study includes two parts a Phase 1 dose escalation and a Phase 2 cohort expansion. STP938 is given orally as a tablet. In Phase 1, participants receive increasing doses of STP938 to find the best dose that can be safely administered. In Phase 2, the drug is given at the determined dose to different groups of patients with various types of B and T cell lymphomas. Blood samples are collected throughout the study to assess the drugs effects on lymphoma and the body. Participants will be monitored for safety, drug absorption, and treatment response for about nine months. Assessments include measuring drug levels in the blood and evaluating tumor response and progression using established lymphoma criteria. The study tracks how well participants tolerate the treatment and how their disease responds, with ongoing safety checks during the study period.

Age: 18Years +All GendersPhase 1Phase 2
15 locations
P

Actively Recruiting

Researchers are studying the effects of fenfluramine hydrochloride compared to a placebo in people with Rett syndrome, a genetic neurological disorder. This Phase 3 clinical trial aims to assess how well fenfluramine hydrochloride works and its safety in improving symptoms of Rett syndrome, with outcomes measured by changes in behavior and clinical impressions over 14 weeks. Participants receive fenfluramine hydrochloride or placebo orally during a 14-week double-blind period, including dose adjustment and maintenance. After this, all participants enter a 2-week transition period, then a 52-week open-label phase where they receive fenfluramine hydrochloride. Those who stop treatment without continued access undergo an 8-day medication taper and a 26-week follow-up. Throughout the trial, participants undergo assessments including questionnaires on behavior, sleep, communication, and caregiver impressions, as well as heart monitoring via ECG and echocardiograms to watch for side effects. Safety and adverse events are tracked up to nearly four years. The study involves regular visits during treatment and follow-up periods, aiming to measure changes in Rett syndrome symptoms and overall clinical status.

Age: 5Years - 35YearsAll GendersPhase 3
40 locations
P

Actively Recruiting

Researchers are studying patients with cirrhosis caused by alcohol-related or metabolic dysfunction-associated steatotic liver disease MASLD. The trial aims to evaluate whether taking capsules containing faecal microbiota from healthy donors can reduce infections and mortality in these patients. This Phase 3 trial follows earlier research that showed faecal microbiota transplantation FMT delivered via endoscopy was safe and feasible, leading to the development of capsules for easier treatment administration. Participants will be randomly assigned to receive either encapsulated FMT or placebo capsules that look identical but contain no active treatment. They will take five capsules every three months over a total period of 21 months or until they develop an infection requiring hospital admission. This double-blind trial means neither participants nor study staff will know which treatment is given. The study will last up to 24 months including follow-up, monitoring effects on infection rates, liver health, immune system function, and antibiotic resistance. Throughout the trial, participants will be regularly assessed for infections, liver disease progression, hospital admissions, quality of life, mental health, alcohol use, and safety of FMT treatment. Laboratory tests will examine immune response and bacterial resistance. The primary outcome is the time until first infection needing hospital care. The study involves detailed monitoring and follow-up visits for up to two years to understand the treatments impact and safety in patients with cirrhosis.

Age: 18Years +All GendersPhase 3
23 locations

1-10 of 218

1